iRadimed Corp (IRMD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Shifts

GuruFocus.com
14 Feb
  • Revenue: $19.4 million for Q4 2024, an 11% increase from Q4 2023; $73.2 million for fiscal year 2024, a 12% increase from 2023.
  • Gross Margin: 76.1% for Q4 2024, slightly down from 76.9% in Q4 2023; 76.9% for fiscal year 2024, up from 76.5% in 2023.
  • Domestic Sales: Increased 21% to $16.5 million in Q4 2024.
  • International Sales: Decreased 24% to $2.9 million in Q4 2024.
  • Device Revenue: Increased 12% to $14.3 million in Q4 2024; 13% to $52 million for fiscal year 2024.
  • Pump Revenue: Increased 34% in Q4 2024; 36% for fiscal year 2024.
  • Operating Expenses: $9 million or 46% of revenue for Q4 2024; $34 million or 47% of revenue for fiscal year 2024.
  • Operating Income: $5.8 million for Q4 2024; $22 million for fiscal year 2024.
  • Net Income (GAAP): $0.40 per diluted share for Q4 2024; $1.50 per diluted share for fiscal year 2024.
  • Net Income (Non-GAAP): $0.44 per diluted share for Q4 2024; $1.66 per diluted share for fiscal year 2024.
  • Cash from Operations: $6 million for Q4 2024, up from $3.9 million in Q4 2023.
  • Free Cash Flow: $2.9 million for Q4 2024, down from $3.3 million in Q4 2023.
  • Warning! GuruFocus has detected 5 Warning Signs with IRMD.

Release Date: February 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • iRadimed Corp (NASDAQ:IRMD) reported a record quarter with revenue exceeding $19.4 million, marking the 14th consecutive record quarter.
  • Gross profit was strong at 76.1%, with GAAP diluted earnings per share increasing by 11% from Q4 2023.
  • Domestic sales increased by 21% to $16.5 million, accounting for 85% of total revenue for Q4 2024.
  • The company has a strong backlog entering 2025, providing good visibility for the first half of the year.
  • The new facility construction is progressing well, with completion expected by June, which will support future growth.

Negative Points

  • International sales decreased by 24% to $2.9 million, indicating challenges in global markets.
  • The gross margin for Q4 2024 was slightly below the previous year's quarter, at 76.1% compared to 76.9%.
  • Operating expenses increased to $9 million, driven by higher sales and marketing expenses.
  • Free cash flow decreased to $2.9 million from $3.3 million in the same period in 2023, due to ongoing capital expenditures.
  • The company faces potential delays in FDA clearance for the new pump, which could impact revenue projections for 2025.

Q & A Highlights

Q: In terms of next year, should we assume that the sales force will focus more on the monitor business, and how do you see 2025 forming on the top line? A: Yes, we will be highlighting sales of the monitor in 2025, and we expect the monitor business to be significantly impacted. We have already seen strong bookings for the monitor in the fourth quarter, indicating more to come in 2025. - Roger Susi, CEO

Q: Has there been a shift in focus of the sales force that contributed to the uptick in monitor business? A: Yes, we made minor tweaks to the sales goals for the monitor versus the pump around midyear last year, which has started to show results in Q4 without impacting the pump business. - Roger Susi, CEO

Q: Will R&D spending decrease now that the pump has been submitted, and what are the expectations for gross margins in 2025? A: R&D spending will remain fairly consistent, with a slight uptick due to potential headcount additions. Gross margins are expected to remain in the 76%-77% range, depending on the geographical mix. - John Glenn, CFO

Q: How are you planning to optimize the sales organization post-approval of the new pump? A: We plan to expand to 35 territories from the current 28, starting in 2025, to prepare for the 2026 launch of the new pump. This will involve adding support staff and clinical specialists. - Roger Susi, CEO

Q: Can you provide insights into the backlog composition and how it might change throughout the year? A: The backlog is currently strong, especially for pumps, but we expect monitors to take a larger portion as the sales team focuses more on them. This gives us good visibility, particularly for the first half of the year. - John Glenn, CFO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10